Trend Exploration Inc (TRDX)

[Neight]

Here’s some DD from post 1145 in 2013

Trend Exploration Inc.
http://www.otcmarkets.com/stock/TRDX/company-info

Contact Info
420 Jericho Turnpike
Jericho, NY 11753

© 2013 Emergency Dental Kit
https://dentalkit.3dcartstores.com/crm.asp?action=contactus

420 Jericho Tpke
Suite 110
Jericho, NY. 11753

http://whois.polodomains.com/domain/FiKAt345GWJkgOiCwjpPIw.._info.html?btid=1

Registrant:
Preferred Distribution Inc.
Joel Falitz
420 Jericho Turnpike Suite 110
Jericho, NY 11753



11/05/09
Trend Exploration to Diversify Business Plan
ATLANTA, GA -- (Marketwire) -- 11/05/09 -- Trend Exploration, Inc. (the "Company") ( TRDX) announces today that the company is in the final stages of developing a business plan that will take the company in directions other than exploration ventures.
The Company believes that, in the best interest of building shareholder value, other opportunities that have been discussed begin to be taken advantage of.
The Company looks forward to the new directions it is entertaining and expects decisions and implementation rapidly.
Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
Trend Exploration
1-866-383-1374

11/10/09
Trend Exploration to Acquire Dental Kit Product Rights
ATLANTA, GA -- (Marketwire) -- 11/10/09 -- Trend Exploration, Inc. ("TRDX" or the "Company") ( TRDX) today announces it is in the process of acquiring the rights to an emergency dental kit product which contains a wide variety of dental treatments for emergency situations ( www.dentalkit.com).
The product in its current form was developed and is owned by Dr. Stahl and its potential for quality sales is vast.
Consumers are also attracted to the idea of a dental emergency kit when they are traveling or unable to reach their dentist. Furthermore, dental emergency kits are also becoming standard issue for sports teams and school nurses.
The Company expects a short timeline to closing of this transaction and the launch of a marketing plan shortly thereafter.
About TRDX
TRDX is a company focused on building a leading holding company for medical and biotech products and services.
Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
1-866-383-1374

11/18/09
Trend Exploration in Discussions to Acquire Preferred Distribution, Inc.
ATLANTA, GA -- (Marketwire) -- 11/18/09 -- Trend Exploration, Inc. ("TRDX" or the "Company") ( TRDX) announces that it has entered advanced acquisitions discussions with Preferred Distribution, Inc., a distributor of medical, dental and healthy & beauty products ("Preferred").
Preferred is a revenue generating company that management feels can be grown aggressively with an increased sales and marketing effort. Preferred's dental products division is marketed through its website, www.preferreddist.com.
The Company will provide updates on this acquisition as developments occur.
About TRDX
TRDX is a company focused on building a leading holding company for medical and bio tech products and services.

12/02/09
Trend Exploration Signs LOI to Secure Rights of Dental Kit Product
ATLANTA, GA -- (Marketwire) -- 12/02/09 -- Trend Exploration, Inc. ("TRDX" or the "Company") ( TRDX) today announces it has executed a Letter of Intent ("LOI") to secure the rights of an emergency dental kit product which contain a wide variety of dental treatments for emergency situations ( www.dentalkit.com).
A definitive agreement and subsequent closing of this transaction is expected shortly.
ABOUT TRDX
TRDX is a company focused on building a leading holding company for medical, dental and bio tech products and services.

12/03/09
Trend Exploration Signs LOI to Acquire Preferred Distribution, Inc., a Revenue Generating Distributo
ATLANTA, GA -- (Marketwire) -- 12/03/09 -- Trend Exploration, Inc. ("TRDX" or the "Company") ( TRDX) today announces it has signed a Letter of Intent ("LOI") to acquire 100% of Preferred Distribution, Inc., a distributor of medical, dental and health & beauty products ("Preferred").
Preferred is a revenue generating company based in the Mineola, NY. Preferred's dental products division is marketed through its website, www.preferreddist.com.
The Company feels confident in its efforts to close this acquisition transaction on a short timeline.
ABOUT TRDX
TRDX is a company focused on building a leading holding company for medical, dental and bio tech products and services.

12/16/09
Trend Expects Current Acquisitions to Execute Definitive Agreements in January
ATLANTA, GA -- (Marketwire) -- 12/16/09 -- Trend Exploration, Inc. ("TRDX" or the "Company") ( TRDX) today confirms that it expects to complete negotiations and subsequent execution of definitive agreements for its planned acquisitions within the month of January, 2010.
About TRDX
TRDX is a company focused on building a leading holding company for medical and biotech products and services.

01/07/10
Trend Updates on Its Mergers and Acquisitions Plans
ATLANTA, GA -- (Marketwire) -- 01/07/10 -- Trend Exploration, Inc. ("TRDX" or the "Company") ( TRDX) today provides an update to its shareholders on its mergers and acquisitions ("M&A") plans.
The Company confirms that negotiations are nearing completion and that it feels it is still on track for signing of final agreements within this month.
The Company looks forward to successful execution of its M&A plans and its ongoing efforts to deliver long-term shareholder value.
About TRDX
TRDX is a company focused on building a leading holding company for medical and bio tech products and services.

06/29/10
TRDX & Genesis Biopharma Introduce Potential Cure for Diabetic Neuropathy
LONG ISLAND, NY -- (Marketwire) -- 06/29/10 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") ( TRDX) recently executed a Letter of Intent with Genesis Biopharma, Inc. ("Genesis") to advance development of a cure to one of the major problems facing people suffering from diabetes -- NEUROPATHY.
Diabetic neuropathy is one of the most severe side effects of diabetes and is caused by the deterioration of nerve fibres in the leg and arm. Neuropathy is manifested by slight numbness or tingling pain in the toes and fingers initially and then migrating to the entire foot, legs, hands, and arms. The risk of getting nerve damage increases with age and the longer an individual has diabetes.
1. According to the World Health Organization there are approximately 220
million people worldwide who have diabetes
( http://www.who.int/mediacentre/factsheets/fs312/en/). In the U.S.,
according to the 2007 National Diabetes Fact Sheet, a total of 23.6
million had diabetes of which 17.9 million were already diagnosed and
the rest, 24%, were undiagnosed
( http://www.diabetes.org/diabetes-basics/diabetes-statistics/). If you
add the undiagnosed cases to the 220 million reported by the World
Health Organization the total number could exceed 270 million worldwide.


2. Diabetes is the leading known cause of neuropathy in developed
countries. It is estimated that the prevalence of neuropathy in diabetes
patients is approximately 20% (See Epidemiology section in
http://en.wikipedia.org/wiki/Diabetic_neuropathy). That results in more
than 50 million estimated cases worldwide and about 5 million estimated
cases in the U.S. of diabetic neuropathy.


3. Diabetic neuropathy can cause nerve damage in the feet that leads to
decrease or loss of sensation. As a result, a blister or a cut can go
unnoticed. Any infection that might ensue can result in tissue death
(gangrene) and in some cases severe damage can lead to amputation of
toe, foot or even leg. Each year about 80,000 - 84,000 amputations are
performed in the U.S. alone (See Diabetes-Related Amputation Statistics:
http://www.isletsofhope.com/diabetes/complications/amputation_1.html#diabetes).
How many of these amputations could have been avoided had a solution
been made available?
Mr. Leo Stella, CEO of Genesis, stated: "Until now, there is absolutely no mechanism based treatment that can reverse neuropathy associated with diabetes. Drugs exist that have a temporary effect on the pain, but these drugs can not cure the cause. As stated above, there are more than 50 Million people worldwide and about 5 million in the U.S. who suffer from nerve damage of some kind that affects their ability to sleep, walk, drive a vehicle, and do just about any task that requires movement without pain. The goal of Genesis Biopharma is to develop a drug that will cure this terrible condition."
Genesis' work includes conducting pre-clinical and clinical trials to develop novel pharmaceutical therapies for the treatment of painful diabetic neuropathy.
Recently, Pre-clinical development has been completed for the treatment of painful diabetic neuropathy [pharmacology, toxicology, ADME (Absorption, Distribution, Metabolism and Excretion) in two species (rodent and non-rodent: rat and dog)] and clinical development (first formulation, part of the stress and stability studies of the drug substance and drug product). In addition, a CTA has been successfully obtained from the Therapeutic Product Directorate (TPD) of Health Canada to initiate Phase I-a clinical trial.
Dr. Jan Stahl, CEO of TRDX, commented: "Genesis has gotten to a key stage of development; we look forward to financing and finalizing our transaction with Genesis and working hard to make this potential cure a reality."
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. ( www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell of every living thing on Earth. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").
About SCIMEDENT f/k/a Trend Exploration, Inc. ( TRDX)
SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
Contact:
SciMeDent Health Corp. f/k/a Trend Exploration, Inc.
[e-mail]
1-866-383-1374

July 9, 2010
TRDX & Genesis Biopharma Announce Dr. Bahige Baroudy as Chief Science Officer to Lead Development of Potential Diabetic Neuropathy Cure
LONG ISLAND, NY–(Marketwire – July 9, 2010) – SciMeDent Health Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces plans to appoint Dr. Bahige Baroudy of Genesis Biopharma to the equivalent role of Chief Science Officer at TRDX for the continued development of a potential cure for diabetic neuropathy.
Dr. Bahige Baroudy has multi-disciplinary expertise in basic research, infectious disease drug discovery and virology. Prior to joining Genesis Biopharma, Dr. Baroudy was a Group Director at Schering-Plough where he spearheaded the development of CCR5 antagonists that are currently in clinical trials as HIV entry inhibitors and earned a place on “The Scientific American 50? list as the top Research Leader in 2003 in this category. He was also the Director, Division of Molecular Virology at the James N. Gamble Institute of Medical Research, where he established research programs in viral hepatitis and liver diseases, HIV/AIDS and vaccinia virus expression and pathogenesis. Dr. Baroudy has also worked at the NIH in several disciplines.
Dr. Baroudy stated: “We are pleased that we have received the approval of Health Canada to proceed to Phase 1 clinical studies.”
Dr. Jan Stahl, CEO of TRDX, commented: “We look forward to the work Dr. Baroudy will execute in bringing this potential cure to market.”

07/26/10
TRDX'S Dental Division Launches New Dental Kit Website; Upcoming Marketing Campaign to Pursue Growth
JERICHO, NY -- (Marketwire) -- 07/26/10 -- SciMeDent Health, Corp f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") ( TRDX) today announces that Preferred Distribution, Inc. ("Preferred"), the Company's medical and dental products subsidiary, has launched the new website for its emergency dental kit ("EDK") product, which contains a wide variety of dental treatments for emergency situations ( www.dentalkit.com).
The upcoming marketing campaign for the Company's EDK is the first in several ways the Company plans to grow Preferred within the large dental supply market to enhance shareholder value.

According to a report by Freedonia, the US dental product and material industry is worth $8.8 billion and is comprised of sales of products (e.g., crowns and bridges, dentures, implants, fillings, orthodontic appliances, veneers, whitening products, adhesives and cements, sealants, fluoride treatments, toothpaste, mouthwash/dental rinse, floss) and raw material.
Preferred Distribution Inc. is a distributor of medical, dental and health & beauty products. Preferred's dental products division is marketed through its dental supply store" website, www.preferreddist.com.
About SCIMEDENT f/k/a Trend Exploration, Inc. ( TRDX)
SciMeDent ( www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
Contact:
SciMeDent Health Corp. f/k/a Trend Exploration, Inc.
www.scimedenthealth.com
[e-mail]
1-866-383-1374

08/03/10
TRDX's Medical & Dental Products Division Signs LOI Exclusive Licensing Rights for "SoleCare(R)," an Innovative, Patent Pending, Podiatry Product
JERICHO, NY -- (Marketwire) -- 08/03/10 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces that Preferred Distribution, Inc., the Company's medical and dental products subsidiary, has signed a Letter of Intent ("LOI") to acquire the exclusive licensing rights to SoleCare®, an innovative, patent pending, podiatry product.
SoleCare® is a unique new product for the removal of calluses by pedicurists.
The Company expects the continuing negotiations to result in a definitive agreement in the near term.
Dr. Gary Wallach, the inventor of SoleCare®, stated: "I am very excited about the decision to work with SciMeDent on the development and distribution of my SoleCare line of products."
Dr. Stahl, CEO of TRDX, commented: "We advanced our discussions from a distribution relationship to an exclusive license deal. Having a license makes us more of a partner with Dr. Wallach and the SoleCare® team."
About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

August 23, 2010
TRDX Announces Signing of Definitive Agreement With Genesis Biopharma, Inc. to Acquire an Exclusive Worldwide Sublicense for a Diabetic Neuropathy Solution
JERICHO, NY--(Marketwire - August 23, 2010) - SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces it has recently executed a Definitive Sublicense Agreement with Montreal-based Genesis Bio Pharma, Inc. to acquire the exclusive worldwide sublicense for a new compound in development for the treatment of Painful Diabetic Neuropathy (PDN).
ABOUT PDN:
PDN is one of many complications of diabetes. Forty to fifty percent of diabetic patients may develop PDN over 15 to 20 years. PDN is present in 11.6% of patients with Type I diabetes and 32.1% of patients with Type II diabetes. PDN may present itself as a progressive build-up of unpleasant sensory symptoms including tingling (paraesthesia), burning pain, radiating pain down the legs and toes and lancinating or contact pain. The pain is more severe during the night and often prevents sleep. Some patients may be in a constant state of tiredness because of sleep deprivation while others are unable to maintain employment.
Dr. Jan Stahl, CEO of TRDX, commented: "The signing of this Definitive Agreement is a major achievement for the development of our partnership with Genesis. We look forward to the closing and working with Genesis to continue the groundbreaking development to treat diabetic neuropathy."
Mr. Leo Stella, CEO of GENESIS Bio Pharma Inc., commented: "We are pleased with the signing of this Agreement and now look forward to the closing so we can move quickly to reach our goals by commencing the clinical trials as soon as possible."
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").
About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
• Contact:
SciMeDent Health Corp. f/k/a Trend Exploration, Inc.
[e-mail]
1-866-383-1374

09/10/10

TRDX Announces Completion of Key Milestone and Provides Details on Closing of Definitive Agreement With Genesis Biopharma, Inc.
JERICHO, NY -- (Marketwire) -- 09/10/10 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today confirms it has completed the structuring of DiabetRX Pharma Corp. ("DiabetRX") which will be assigned the Sublicense and upon Final Closing will be 100% owned by TRDX.
In addition, the Company provides the following details regarding the recently executed Definitive Sublicense Agreement ("Definitive") with Montreal-based Genesis Biopharma, Inc. ("Genesis").
General Terms:

Financing TRDX has committed to a financing of $800,000 for the
continued R&D of Genesis' Painful Diabetic Neurapathy
("PDN") solution

The financing can be completed in tranches, with each
tranche resulting in a pro-rated ownership of DiabetRX.

First Tranche $60,000 required to maintain sublicense and take possession
of the first 7.5% of DiabetRX

Initial Closing The Initial Closing is based on, amongst other items, the
completion of customary due diligence by the parties

Final Closing Final Closing is defined as the completion of the $800,000
financing for the development of the PDN solution
Dr. Jan Stahl, CEO of TRDX, commented: "Since the signing of the Definitive Agreement, I am very happy with the progress we have made with Genesis. We feel confident in the current steps we are taking to complete the Initial Closing and first Tranche financing. We view DiabetRX as a long term investment with large potential and look forward to the Final Closing."

September 13, 2010
TRDX and Genesis Biopharma, Inc. Believe the Future Looks Bright Regarding Their Potential Cure for Painful Diabetic Neuropathy (PDN) — A Billion…
JERICHO, NY–(Marketwire – September 13, 2010) – SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces that it believes that the future looks very bright for itself and its sublicense partner, Montreal-based Genesis Biopharma, Inc., as they continue making progress regarding their new compound in development for the treatment and potential cure of Painful Diabetic Neuropathy (PDN).
According to the International Diabetes Federation the global health expenditure on diabetes is expected to total at least USD 376 billion in 2010 and USD 490 billion in 2030. (http://www.idf.org/webdata/docs/PIIS0168822710000495.pdf)
Back in 2003 the American Diabetes Association estimated that in the U.S. the total annual cost of treating diabetic peripheral neuropathy and its complications was $10.91 billion. (http://care.diabetesjournals.org/content/26/6/1790.full)
ABOUT PDN:
PDN is one of many complications of diabetes. Forty to fifty percent of diabetic patients may develop PDN over 15 to 20 years. PDN is present in 11.6% of patients with Type I diabetes and 32.1% of patients with Type II diabetes. PDN may present itself as a progressive build-up of unpleasant sensory symptoms including tingling (paraesthesia), burning pain, radiating pain down the legs and toes and lancinating or contact pain. The pain is more severe during the night and often prevents sleep. Some patients may be in a constant state of tiredness because of sleep deprivation while others are unable to maintain employment.
1. According to the World Health Organization there are approximately 220 million people worldwide who have diabetes
(http://www.who.int/mediacentre/factsheets/fs312/en/). In the U.S., according to the 2007 National Diabetes Fact Sheet, a total of 23.6 million had diabetes of which 17.9 million were already diagnosed and the rest, 24%, were undiagnosed.
(http://www.diabetes.org/diabetes-basics/diabetes-statistics/). If you add the undiagnosed cases to the 220 million reported by the World Health Organization the total number could exceed 270 million worldwide.
2. Diabetic neuropathy can cause nerve damage in the feet that leads to decrease or loss of sensation. As a result, a blister or a cut can go unnoticed. Any infection that might ensue can result in tissue death (gangrene) and in some cases severe damage can lead to amputation of toe, foot or even leg. Each year about 80,000 – 84,000 amputations are performed in the U.S. alone (See Diabetes-Related Amputation Statistics:
http://www.isletsofhope.com/diabetes/complications/amputation_1.html#diabetes).
How many of these amputations could have been avoided had a solution been made available?
Mr. Leo Stella, CEO of Genesis, has stated: “Until now, there is absolutely no mechanism based treatment that can reverse neuropathy associated with diabetes. Drugs exist that have a temporary effect on the pain, but these drugs cannot cure the cause. The goal of Genesis Biopharma is to develop a drug that will cure this terrible condition.”
Dr. Jan Stahl, CEO of TRDX, commented: “The opportunity is very significant for all the stakeholders in this PDN solution. We will continue our efforts to make this potential cure a reality and deliver quality value for our shareholders.”

January 4, 2011
TRDX to Seek Growth Through Launch of Pharmaceutical Distribution Division; Currently Approved in New York & Florida, Other States Pending
JERICHO, NY--(Marketwire - January 4, 2011) - SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces that Preferred Distribution, Inc., its medical and dental supplies distribution subsidiary ("Preferred") (www.preferreddist.com), is in the process of launching a pharmaceutical distribution division.
The implementation which initially consists of Preferred registering as an out of state wholesaler of pharmaceuticals is well underway. Preferred has successfully registered in New York, Florida and Washington. Additional registrations are pending in New Jersey and California.
Dr. Jan Stahl, CEO of TRDX, commented: "Preferred has been working for quite some time to prepare for this new division. This new division provides the Company with a tremendous opportunity for significant revenue growth. We look forward to its implementation and the value it could possibly bring to the Company and its shareholders."
About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

January 24, 2011
TRDX's Wholly Owned Subsidiary, Preferred Distribution, Inc., Announces Its New Pharmaceutical Distribution Division Has Been Approved as a Distributor for Global Pharmaceutical Wholesaler, Hospira
JERICHO, NY--(Marketwire - January 24, 2011) - SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce, Preferred Distribution, Inc. ("Preferred"), its medical and dental supplies distribution subsidiary, has recently been approved as a distributor for Hospira, a global pharmaceutical wholesaler (www.hospira.com). This distribution relationship now provides Preferred's pharmaceutical division with new products for its distribution pipeline.
The distributorship with Hospira is the first to be completed by Preferred. More dealerships are being pursued as sources of product. Management anticipates the pharmaceutical distribution division will provide a significant source of additional revenue for the company in 2011.
The Company looks forward to announcing more developments as milestones are successfully achieved.
About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
About Hospira
Hospira is a global specialty pharmaceutical and medication delivery company, backed by proven leadership and more than 70 years' experience producing high-quality products. Hospira's breadth of offerings help customers address the safety, productivity and cost of patient care. Used by hospitals worldwide, Hospira products are also prevalent in outpatient clinics and other alternate healthcare sites.

February 2, 2011
TRDX Dental Supply Division to Launch New Emergency Dental Kits Into Emergency Rooms and Nursing Homes
Demand for Emergency Dental Kits on Rise Domestically and Internationally
JERICHO, NY--(Marketwire - February 2, 2011) - SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce its wholly owned subsidiary Preferred Distribution Inc. is in the process of launching two new versions of its Emergency Dental Kit ("EDK"). These kits are specifically designed to be used in emergency rooms and nursing homes. Management anticipates this new product will continue to accelerate the Company's revenue in 2011. As previously announced, the Company's revenues (unaudited) for 2010 are expected to exceed one million dollars.
Preferred, currently markets its standard EDK through www.dentalkit.com.
EDK's contain a wide variety of temporary dental treatments for emergency situations. Consumers utilize the dental emergency kit when they are traveling or are unable to reach their dentist. Furthermore, dental emergency kits are also becoming standard items for sports teams and school nurses.
Dr. Jan Stahl, CEO of TRDX, commented, "The need for temporary emergency dental treatment in an ER or at a nursing home is important in situations when a dentist is not on site. We believe this presents an opportunity for customized versions of our standard EDK for hospital ERs and nursing home facilities. We believe that is there not only a large domestic market, but we also feel we can expand internationally with these two new versions of our kit."
Preferred Distribution Inc. is a distributor of medical, dental and health & beauty products ("Preferred"). Preferred's dental products division is marketed through its website, www.preferreddist.com.


February 03, 2011
TRDX Prepares for Additional Revenue Stream From Its New Pharmaceutical Distribution Division
IMS Health Reports Pharmaceutical Market to Generate $1.1 Trillion in Sales by 2014
JERICHO, NY--(Marketwire - February 3, 2011) - SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX), is pleased to announce their wholly owned subsidiary Preferred Distribution, Inc. (Preferred), is on target to launch their new pharmaceutical distribution division by the second quarter of 2011. This division has already received approval by global pharmaceutical wholesaler Hospira, to distribute their products. Preferred's new pharmaceutical division will provide a third source of revenue for the Company. The pharmaceutical market is one of the fastest growing industries with long-term growth.
In an article dated April 20, 2010, IMS Health reported that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading products losing patent protection in developed markets, as well as strong overall growth in the world's emerging countries.
To read the full article, please click on the link: http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=4b8c410b6c718210VgnVCM100000ed152ca2RCRD&vgnextchannel=b5e57900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default
Dr. Jan Stahl, TRDX CEO, stated: "This is an exciting time for our company. Our new pharmaceutical division is anticipated to provide revenue growth in a rapidly growing industry. We have already received approval from global pharmaceutical wholesaler Hospira, to distribute their products. We anticipate receiving approval for distribution from other pharmaceutical wholesalers in the near-term."
About SciMeDent f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
About Preferred Distribution, Inc.
Preferred Distribution, Inc. is a wholly owned subsidiary of SciMeDent. Preferred's goal is to supply the medical, dental and veterinary community with quality products at the lowest possible prices. Preferred prides itself on providing professional sales staff who are courteous, knowledgeable and dedicated to saving you time and money for your practice. Since 1987 Preferred has been serving the needs of professionals throughout the country. Preferred's dental products division is marketed through its website, www.preferreddist.com.

02/08/11
TRDX Dental Division Completes Test Market of "BLAST" -- a New Innovative Commercial Dental Suction System Cleaner
Demand for Product Anticipated to Boost Company's Revenues
JERICHO, NY -- (Marketwire) -- 02/08/11 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce that is has completed a test market study for its new commercial dental suction system cleaner, "BLAST," and is now developing its sales and marketing plan for a national launch of the product.
• BLAST is a unique Dental Evacuation System Cleaner
o BLAST is an effective combination of enzyme-creating bacteria and super charged cleaning agents which immediately break down and "eat" organic matter leaving your suction lines clean and deodorized. These bacteria form a living biofilm in the suction lines of the system and work 24/7 dissolving organic matter. Treatment consists only of 4 oz used 2-3 times a week, by utilizing our tip and pour dispenser that saves time and money.
Dr. Jan Stahl, CEO of TRDX, commented, "BLAST is innovative evacuation cleaner that not only saves time and money, but works continuously even when the dental office is closed. Economical and easier to use than current cleaners, Blast will maintain the system and prevent costly repairs. We are pleased with the results of our test marketing and we look forward to bringing this product to dental offices nationwide and feel it could be a good source of additional revenue for the Company."

02/15/11
TRDX Pharmaceutical Division Approved for the State of Louisiana Distribution License
Pharmaceutical Division Anticipated to Provide Another Strong Infusion of Revenue
JERICHO, NY -- (Marketwire) -- 02/15/11 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce its wholly owned subsidiary Preferred Distribution, Inc. ("Preferred") has been approved in the State of Louisiana for its out of state wholesale pharmaceutical distribution license.
Currently, Preferred has received approval in New York, Florida, Washington and now Louisiana. Additional registrations are pending in New Jersey and California with approvals expected within 30-60 days.
Pharmaceutical distribution is one of the fastest growing sectors in the world. Preferred anticipates their new pharmaceutical division will provide an additional major source of revenue into the company. In January of 2011, management reported Year End 2010 revenues (unaudited) will exceed one million dollars. Year End 2011 revenues are now expected to surpass 2010 revenues.
Dr. Jan Stahl, CEO of TRDX, commented: "We recently received our license and now look forward to our planned 2nd quarter launch. We believe this approval is another key step towards another year of strong revenue growth for the Company."

February 21, 2011
TRDX Anticipates Year End 2011 Revenues of $1.25 Million and Year End 2012 Revenues of $1.6 Million
JERICHO, NY--(Marketwire - February 21, 2011) - SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) today provides an outlook to its shareholders on its next 12-24 months of operations.
The Company believes that upon receiving a modest amount of funding (approximately $250,000), that its wholly owned subsidiary Preferred Distribution, Inc. can grow its revenue by at least 25% each of the next two fiscal years. Specifically, the Company's goals are to grow from $1,000,000 in estimated revenue for 2010 to a minimum of $1,250,000 in forecasted revenue for Year End 2011. Year End 2012 revenues are estimated to be a minimum of $1,600,000 in forecasted revenue.
The forecasted income is based on the Company's plans to grow its revenue from the upcoming launch of its new pharmaceutical wholesale division, online marketing of its dental supply store (www.preferreddist.com), sales of previously announced new products such as Emergency Dental Kits (www.dentalkit.com) and Blast, a New Innovative Commercial Dental Suction System Cleaner.
Dr. Jan Stahl, CEO of TRDX, commented: "We are currently in discussion for the funding required to accomplish our goals and feel confident that upon receiving a minimum of $250,000, the Company can market its products effectively to reach forecasted revenues."
About SciMeDent f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
About Preferred Distribution, Inc.
Preferred Distribution, Inc. is a wholly owned subsidiary of SciMeDent. Preferred's goal is to supply the medical, dental and veterinary community with quality products at the lowest possible prices. Preferred prides itself on providing professional sales staff who are courteous, knowledgeable and dedicated to saving you time and money for your practice. Since 1987 Preferred has been serving the needs of professionals throughout the country. Preferred's dental products division is marketed through its website, www.preferreddist.com.

03/02/11
TRDX's Wholly Owned Subsidiary Preferred Distribution, Inc. Announces Its New Pharmaceutical Distribution Division Has Been Approved as a Distributor for Regional Pharmaceutical Wholesaler, Bellco
Bellco Is a Wholesaler of Over 20,000 Branded and Generic Products
JERICHO, NY -- (Marketwire) -- 03/02/11 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce Preferred Distribution, Inc. ("Preferred"), its medical/dental supplies distribution subsidiary, has recently been approved as a distributor for Bellco (www.bellcoonline.com), a regional pharmaceutical wholesaler of over 20,000 branded and generic products, including pharmaceuticals, OTC, and health & beauty products.
This distribution relationship now provides Preferred's pharmaceutical division with new products for its distribution pipeline.
The recent approval with Bellco is the second to be completed by Preferred, including global wholesaler, Hospira. Additional distributorships are being pursued as sources of product.
Management anticipates the pharmaceutical distribution division will provide a significant source of additional revenue for the Company in 2011.
The Company looks forward to announcing more developments as milestones are successfully achieved.

03/09/11
TRDX's New Pharmaceutical Distribution Division Now Generating Purchase Orders
Management Reiterates Forecasts of 25% Increase in 2011 Sales to $1.25 Million
JERICHO, NY -- (Marketwire) -- 03/09/11 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce that Preferred Distribution, Inc. ("Preferred"), its medical/dental supplies distribution subsidiary, has recently generated purchase orders from its new pharmaceutical distribution division. The first stream of purchase orders are being filled under its Florida out of state wholesaler of pharmaceuticals license.
Dr. Jan Stahl, CEO of TRDX, commented, "We are happy with the progress of this new division. The pharmaceutical wholesale sector is one of the fastest sales generators in the world. IMS Health reported that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014."
Mr. Stahl further stated, "This growth and demand falls in line with what our new pharmaceutical division is experiencing. We have already received approvals from two large pharmaceutical wholesalers and have now begun receiving purchase orders. We anticipate a continued increase in purchase orders and remain confident on achieving $1.25 million in total sales from Preferred for year end 2011. This is a 25% year over year increase from 2010. Accelerated growth is again projected for year end 2012 as existing sales increase and contracts with new pharmaceutical wholesalers are signed."

March 22, 2011
TRDX's New Pharmaceutical Distribution Division Books Revenue From Earlier Than Expected Sales
JERICHO, NY--(Marketwire - March 22, 2011) - SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce that Preferred Distribution, Inc. ("Preferred"), its medical/dental supply distribution subsidiary, has received payment from its recently generated purchase orders from its new pharmaceutical distribution division. These booked sales have generated revenue on an earlier than expected timeframe.
Dr. Jan Stahl, CEO of TRDX, stated, "We are pleased with the initial sales for our new pharmaceutical division. We look forward to our official launch of this new division in the second quarter and further growth in Preferred's revenue."
The pharmaceutical wholesale sector is one of the fastest sales generators in the world. IMS Health reported that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014.
About SciMeDent f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
About Preferred Distribution, Inc.
Preferred Distribution, Inc. is a wholly owned subsidiary of SciMeDent. Preferred's goal is to supply the medical, dental and veterinary community with quality products at the lowest possible prices. Preferred prides itself on providing professional sales staff who are courteous, knowledgeable and dedicated to saving you time and money for your practice. Since 1987 Preferred has been serving the needs of professionals throughout the country. Preferred's dental products division is marketed through its website, www.preferreddist.com.

03/24/11
TRDX Dental Supply Store to Expand Marketing Plan Through Addition of Outside Sales Reps
Market for Dental Product Is Forecasted to Reach $11 Billion in 2012
JERICHO, NY -- (Marketwire) -- 03/24/11 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce its wholly owned subsidiary Preferred Distribution Inc. ("Preferred") is in the process of expanding its marketing efforts for its dental supply store (www.preferreddist.com). Specifically, outside sales reps are planned to be hired in various regions of the USA to boost the sales for Preferred's products. Initial plans are to hire reps in California and Florida.
Demand for dental products (excluding equipment) in the U.S. is forecasted to rise 4.5 percent per year to nearly $11 billion in 2012 (report published by Freedonia).
Dr. Jan Stahl, CEO of TRDX, commented, "The dental supply industry is a large market with potential for Preferred to grow within. These expanded marketing plans are expected to increased demand and ultimately boost our revenues."
About SciMeDent f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.
About Preferred Distribution, Inc.
Preferred Distribution, Inc. is a wholly owned subsidiary of SciMeDent. Preferred's goal is to supply the medical, dental and veterinary community with quality products at the lowest possible prices. Preferred prides itself on providing professional sales staff who are courteous, knowledgeable and dedicated to saving you time and money for your practice. Since 1987 Preferred has been serving the needs of professionals throughout the country. Preferred's dental products division is marketed through its website, www.preferreddist.com.

19 June 2011
http://www.zoominfo.com/p/Jan-Stahl/1417419602
www.scimedenthealth.com, 19 June 2011 [cached]
SciMedent is led By Dr. Jan Stahl. Dr. Stahl brings 25 years of experience in the medical and dental products industry to TRDX. His experience in both public and private companies, will be a key force behind the development and growth of the Company.

(The Diabetic-Deal was canceled)